Allogeneic stem cell transplantation for autoimmune diseases: Nonmyeloablative conditioning regimens

Bone Marrow Transplantation

Volumn 32, Issue , 2003, Pages S81-S83

  Oyama, Y ^a   Traynor, A E ^a   Barr, W ^a   Burt, R K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GANCICLOVIR; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PREDNISONE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; CASE REPORT; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; KIDNEY FAILURE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; UNITED STATES;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CLINICAL TRIALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PATIENT SELECTION; SCLERODERMA, SYSTEMIC; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0041410153     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703950     Document Type: Article

References (16)

1. Hinterberger W, Hinterberger-Fischer M, Marmont AM. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favourably affects outcomes after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant 2002; 11: 753-759.
2. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukaemia and severe psoriasis and psoriatic polyarthritis. Exp Hematol 2000; 28: 853-857.
3. Li H, Kaufman CL, Boggs SS et al. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J Immunol 1996; 156: 380-388.
4. Wang B, Yamamoto Y, El-Badri NS, Good NA. Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice. Proc Nat Acad Sci USA 1999; 96: 3012-3016.
5. Wang BY, Cherry, El-Badri NS, Good RA. Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation. Proc Nat Acad Sci USA 1997; 94: 12065-12069.
6. Delaney CP, Murase N, Chen-Woan M et al. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo-and autoimmunity. J Clin Invest 1996; 97: 217-225.
7. Gaur LK, Kennedy E, Nitta Y et al. Induction of donorspecific tolerance to islet allografts in nonhuman primates. Ann NY Acad Sci 2002; 958: 194-198.
8. Wu T, Levay-Young B, Heuss N et al. Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy. Transplantation 2002; 74: 22-27.
9. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthrits Rheum 1994; 37: 481-494.
10. Erhardt CC, Mumford PA, Venables PJ, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight-year prospective study. Ann Rheum Dis 1989; 48: 7-13.
11. Prior P, Symmons DPM, Scott DL et al. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984; 23: 92-99.
12. Medsger TA, Masi AT, Rodnan GP et al. Survival with systemic sclerosis (scleroderma). Ann Intern Med 1971; 75: 369-376.
13. Wynn J, Fineberg N, Matzer L et al. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985; 110: 123-127.
14. Altman RD, Medsger Jr TA, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-413.
15. Bryan C, Knight C, Black CM, Silman AJ. Prediction of fiveyear survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660-2667.
16. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy 2001; 3: 197-201.